U.S. Markets close in 3 hrs 33 mins

See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc.

IHS Markit

Valeant Pharmaceuticals International Inc

NYSE:VRX

Score: Neutral (64)

7 days at current score.

Upgraded from Negative on September 15th 2017

View full report here!

Summary


  • This company ranked positively in 3 out of 4 IHS Markit Categories but is neutral compared to the Healthcare sector
  • Perception of the company's creditworthiness is positive but weakening
  • Bearish sentiment is low
  • Economic output in this company's sector is expanding


Bearish sentiment

Short interest | Positive

Short interest is low for VRX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

Money flow

ETF/Index ownership | Neutral

ETF activity is neutral. ETFs that hold VRX had net inflows of $1.47 billion over the last one-month.

Economic sentiment

PMI by IHS Markit | Positive

According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year.

Credit worthiness

Credit default swap | Positive

The current level displays a positive indicator with a weakening bias over the past 1-month. Although VRX credit default swap spreads are rising, indicating some deterioration in the market's perception of the company's credit worthiness, they are among the lowest levels seen during the last one year.

Please send all inquiries related to the report to score@ihsmarkit.com.

Charts and report PDFs will only be available for 30 days after publishing.

This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.